Exploring the Safety and Efficacy of Direct Oral Anticoagulants (DOACs) in Vulnerable Patient Populations
June 11, 2024
Target Audience
All pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to:
- Describe the mechanism, dosing, indications, adverse drug reactions of DOACs
- Evaluate recommendations provided by guidelines including 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation and American Society of Hematology Treatment of VTE or Pulmonary Embolism regarding DOACs usage in vulnerable patient populations
- Analyze literature utilizing DOACs in individuals with extreme weight, advanced age, or kidney impairment
- Summarize the safety and efficacy of utilizing DOACs in the vulnerable patient population based on the primary literature
ZOOM or Brooklyn Hospital
United States
Pauletta Lazarevskiy, PGY-1 Pharmacy Resident, PharmD.
Pauletta Lazarevskiy graduated from the Arnold and Marie Schwartz College of Pharmacy and Health Sciences at Long Island University in 2023 and is a PGY1 pharmacy resident at The Brooklyn Hospital Center. Starting this July, she will begin her Ambulatory Care PGY-2 at The Brooklyn Hospital Center.
ACPE UAN 0042-0000-24-036-L01-P
Available Credit
- 1.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.